Following CLIA Lab Buy, Life Tech Jumps into MDx Space with Purchase of Pinpoint, Lung Cancer Dx | GenomeWeb

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

This week, the life sciences tools vendor announced it would acquire Pinpoint Genomics in order to get its hands on a prognostic test that can identify which early-stage non-small cell lung cancer patients are at high risk for experiencing disease progression during the five-year window after surgical resection of their tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.